The stock price of Annovis Bio Inc (NYSE: ANVS) has jumped by 5.00 compared to previous close of 2.80. Despite this, the company has seen a fall of -3.61% in its stock price over the last five trading days. zacks.com reported 2025-06-11 that Annovis Bio (ANVS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company’s earnings prospects. This might drive the stock higher in the near term.
Is It Worth Investing in Annovis Bio Inc (NYSE: ANVS) Right Now?
The 36-month beta value for ANVS is at 1.62. Analysts have varying views on the stock, with 2 analysts rating it as a “buy,” 2 rating it as “overweight,” 1 as “hold,” and 0 as “sell.”
The public float for ANVS is 16.65M, and currently, shorts hold a 12.69% of that float. The average trading volume for ANVS on June 13, 2025 was 439.27K shares.
ANVS’s Market Performance
ANVS stock saw an increase of -3.61% in the past week, with a monthly gain of 72.94% and a quarterly increase of 78.18%. The volatility ratio for the week is 4.90%, and the volatility levels for the last 30 days are 8.34% for Annovis Bio Inc (ANVS). The simple moving average for the past 20 days is 18.88% for ANVS’s stock, with a -38.16% simple moving average for the past 200 days.
Analysts’ Opinion of ANVS
Maxim Group, on the other hand, stated in their research note that they expect to see ANVS reach a price target of $25. The rating they have provided for ANVS stocks is “Buy” according to the report published on October 25th, 2024.
Canaccord Genuity gave a rating of “Buy” to ANVS, setting the target price at $36 in the report published on December 29th of the previous year.
ANVS Trading at 58.22% from the 50-Day Moving Average
After a stumble in the market that brought ANVS to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -83.56% of loss for the given period.
Stock Fundamentals for ANVS
The total capital return value is set at -0.78. Equity return is now at value -280.78, with -168.22 for asset returns.
Currently, EBITDA for the company is -22.74 million with net debt to EBITDA at 1.18. The liquidity ratio also appears to be rather interesting for investors as it stands at 10.68.
Conclusion
In conclusion, Annovis Bio Inc (ANVS) has had a mixed performance lately. Opinion on the stock among analysts is bullish, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
